SATB1 promotes MDR in gastric cancer by regulation of Ezrin to alter subcellular localization of ABC transporters

Jiajun Luo,Jingwen Yuan,Yu Yang,Yue Jiang,Junfeng Yan,Qiang Tong
DOI: https://doi.org/10.1111/cas.15693
IF: 5.7
2022-12-17
Cancer Science
Abstract:Multidrug resistance is a primary factor in the poor response to chemotherapy and subsequent death in gastric cancer patients. However, the molecular mechanisms involved remain unclear. In this study, the high expression of Special AT‐rich sequence binding protein 1 (SATB1) in gastric cancer was found to be associated with reduced sensitivity to various chemotherapy drugs. Our results demonstrate that SATB1 can promote chemotherapy resistance in gastric cancer in vitro and in vivo. SATB1 exerts its effect by enhancing the activity of multiple ATP‐binding cassette (ABC) transporters (P‐glycoprotein, multidrug resistance‐associated protein, and breast cancer resistance protein) in gastric cancer cell lines. We also found that SATB1 affects ABC transporters by altering the subcellular localization of the ABC transporter rather than its expression. Subsequently, we confirmed that Ezrin binds to various ABC transporters and affects their subcellular localization. In addition, we found that SATB1 can also bind to the Ezrin promoter and regulate its expression. Altogether, we elucidate the mechanism of SATB1‐mediated multidrug resistance in gastric cancer, providing a basis for SATB1 as a potential target for reversal of resistance.
oncology
What problem does this paper attempt to address?